PROCEPT BioRobotics (PRCT) Expected to Announce Earnings on Tuesday

PROCEPT BioRobotics (NASDAQ:PRCT) is projected to release its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect PROCEPT BioRobotics to post earnings of ($0.32) per share and revenue of $93.7040 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

PROCEPT BioRobotics Stock Performance

PRCT opened at $27.27 on Friday. The firm has a fifty day moving average price of $30.83 and a 200 day moving average price of $34.00. PROCEPT BioRobotics has a 1 year low of $26.23 and a 1 year high of $70.80. The stock has a market cap of $1.52 billion, a P/E ratio of -17.82 and a beta of 0.99. The company has a debt-to-equity ratio of 0.14, a current ratio of 8.44 and a quick ratio of 7.20.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on PRCT shares. Piper Sandler reiterated an “overweight” rating and issued a $50.00 price objective (down previously from $55.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, November 5th. Wells Fargo & Company cut their price target on PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Morgan Stanley reduced their price target on PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating for the company in a report on Tuesday, December 2nd. Bank of America reiterated a “neutral” rating and set a $38.00 price target (down previously from $55.00) on shares of PROCEPT BioRobotics in a research report on Monday, December 8th. Finally, Leerink Partners restated an “outperform” rating and issued a $55.00 price objective on shares of PROCEPT BioRobotics in a research report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $53.40.

Institutional Trading of PROCEPT BioRobotics

Institutional investors have recently made changes to their positions in the company. T. Rowe Price Investment Management Inc. increased its position in shares of PROCEPT BioRobotics by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after purchasing an additional 1,218,815 shares in the last quarter. Invesco Ltd. boosted its stake in PROCEPT BioRobotics by 19.8% during the 4th quarter. Invesco Ltd. now owns 43,570 shares of the company’s stock worth $1,371,000 after purchasing an additional 7,191 shares during the last quarter. EP Wealth Advisors LLC purchased a new stake in shares of PROCEPT BioRobotics during the fourth quarter worth $300,000. Mackenzie Financial Corp grew its holdings in shares of PROCEPT BioRobotics by 8.2% during the fourth quarter. Mackenzie Financial Corp now owns 1,573,405 shares of the company’s stock worth $49,512,000 after buying an additional 118,971 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of PROCEPT BioRobotics in the fourth quarter valued at about $3,547,000. 89.46% of the stock is owned by institutional investors and hedge funds.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.